Long-term Outcomes of Adalimumab Therapy in Korean Patients with Ulcerative Colitis: A Hospital-Based Cohort Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking. Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the Asan Medical Center, Seoul, Korea. Results: Between July 2013 and October 2018, adalimumab therapy was started in a total of 100 patients with UC (65 males [65.0%]; median age, 39.5 years [interquartile range, 23.3 to 49.8 years]; and median disease duration, 3.0 years [interquartile range, 1.0 to 7.0 years]). The median duration of adalimumab therapy was 13.5 months (interquartile range, 4.0 to 32.0 months). Eight of 100 patients (8.0%) received induction therapy only, four (4.0%) of whom ultimately underwent colectomy. Of 92 patients who received adalimumab maintenance therapy, 30 (30.0%) stopped adalimumab therapy due to loss of response, and one patient (1.0%) was lost to follow-up. Among the 92 patients who received adalimumab maintenance therapy, the cumulative proportions of patients remaining on adalimumab maintenance therapy were 70.0% at 1 year and 48.9% at 5 years. High partial Mayo score after 8 weeks of adalimumab therapy (hazard ratio [HR], 1.217; 95% confidence interval [CI], 1.040 to 1.425; p=0.014) and a history of exposure to two biologic agents before adalimumab therapy (HR, 4.722; CI, 1.033 to 21.586; p=0.045) were predictors of adalimumab discontinuation. Conclusions: Long-term outcomes of adalimumab therapy in Korean UC patients appear to be comparable to those in previously published Western studies. Furthermore, previous exposure to multiple biologic agents before adalimumab therapy and disease activity after 8 weeks of adalimumab therapy were predictors of adalimumab discontinuation.
Abstract
Background/Aims: Studies on long-term outcomes of adalimumab therapy in non-Caucasian patients with ulcerative colitis (UC) are lacking. Methods: We analyzed long-term outcomes of Korean UC patients treated with adalimumab at the Asan Medical Center, Seoul, Korea. Results: Between July 2013 and October 2018, adalimumab therapy was started in a total of 100 patients with UC (65 males [65.0%]; median age, 39.5 years [interquartile range, 23.3 to 49.8 years]; and median disease duration, 3.0 years [interquartile range, 1.0 to 7.0 years]). The median duration of adalimumab therapy was 13.5 months (interquartile range, 4.0 to 32.0 months). Eight of 100 patients (8.0%) received induction therapy only, four (4.0%) of whom ultimately underwent colectomy. Of 92 patients who received adalimumab maintenance therapy, 30 (30.0%) stopped adalimumab therapy due to loss of response, and one patient (1.0%) was lost to follow-up. Among the 92 patients who received adalimumab maintenance therapy, the cumulative proportions of patients remaining on adalimumab maintenance therapy were 70.0% at 1 year and 48.9% at 5 years. High partial Mayo score after 8 weeks of adalimumab therapy (hazard ratio [HR], 1.217; 95% confidence interval [CI], 1.040 to 1.425; p=0.014) and a history of exposure to two biologic agents before adalimumab therapy (HR, 4.722; CI, 1.033 to 21.586; p=0.045) were predictors of adalimumab discontinuation. Conclusions: Long-term outcomes of adalimumab therapy in Korean UC patients appear to be comparable to those in previously published Western studies. Furthermore, previous exposure to multiple biologic agents before adalimumab therapy and disease activity after 8 weeks of adalimumab therapy were predictors of adalimumab discontinuation.
참고문헌 (23)
- Poullenot F, "First line therapy of inflammatory bowel disease", Rev Prat, 64, pp.1242~1248 (2014)
- Lee HS, "Long-term prognosis of ulcerative colitis and its temporal change between 1977 and 2013 : a hospital-based cohort study from Korea", J Crohns Colitis, 9, pp.147~155 (2015)
- Reinisch W, "Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis : results of a randomised controlled trial", Gut, 60, pp.780~787 (2011)
- Sandborn WJ, "One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab : subgroup analyses from ULTRA 2", Aliment Pharmacol Ther, 37, pp.204~213 (2013)
- Sandborn WJ, "Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis", Gastroenterology, 142, pp.257~265 (2012)
- Feagan BG, "Adalimumab therapy is associated with reduced risk of hospitalization in patients with ulcerative colitis", Gastroenterology, 146, pp.110~118 (2014)
- Afif W, "Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab", Inflamm Bowel Dis, 15, pp.1302~1307 (2009)
- Suzuki Y, "Four-year maintenance treatment with adalimumab in Japanese patients with moderately to severely active ulcerative colitis", J Gastroenterol, 52, pp.1031~1040 (2017)
- Suzuki Y, "Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis", J Gastroenterol, 49, pp.283~294 (2014)
- Silverberg MS, "Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease : report of a Working Party of the 2005 Montreal World Congress of Gastroenterology", Can J Gastroenterol, 19, pp.5A~36A (2005)
- Jang EY, "Diagnostic performance of the cytomegalovirus(CMV)antigenemia assay in patients with CMV gastrointestinal disease", Clin Infect Dis, 48, pp.e121~e124 (2009)
- Park SH, "Severe disease activity and cytomegalovirus colitis are predictive of a nonresponse to infliximab in patients with ulcerative colitis", Dig Dis Sci, 58, pp.3592~3599 (2013)
- Kim JW, "Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis", J Crohns Colitis, 8, pp.693~701 (2014)
- Rahier JF, "Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease", J Crohns Colitis, 8, pp.443~468 (2014)
- Lee HS, "Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe ulcerative colitis", Inflamm Bowel Dis, 22, pp.912~918 (2016)
- Bálint A, "Efficacy and safety of adalimumab in ulcerative colitis refractory to conventional therapy in routine clinical practice", J Crohns Colitis, 10, pp.26~30 (2016)
- Italian Group for the Study of Inflammatory Bowel Disease, "Adalimumab in active ulcerative colitis: a “real-life” observational study", Dig Liver Dis, 45, pp.738~743 (2013)
- Hussey M, "Long-term assessment of clinical response to adalimumab therapy in refractory ulcerative colitis", Eur J Gastroenterol Hepatol, 28, pp.217~221 (2016)
- Mizoshita T, "Prospective comparison of preference and efficacy of adalimumab and infliximab for treating ulcerative colitis naive to antitumor necrosis factor therapy", Medicine(Baltimore), 96, pp.e7800~ (2017)
- Taxonera C, "Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab", Aliment Pharmacol Ther, 33, pp.340~348 (2011)
- McDermott E, "Efficacy of Adalimumab as a long term maintenance therapy in ulcerative colitis", J Crohns Colitis, 7, pp.150~153 (2013)
- Papamichael K, "Post-induction adalimumab concentration is associated with short-term mucosal healing in patients with ulcerative colitis", J Crohns Colitis, 11, pp.53~59 (2017)
- Park SH, "Long-term prognosis of Crohn’s disease and its temporal change between 1981 and 2012 : a hospital-based cohort study from Korea", Inflamm Bowel Dis, 20, pp.488~494 (2014)